摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-3-(3-methylpiperidin-1-yl)propan-1-ol | 862311-76-0

中文名称
——
中文别名
——
英文名称
(S)-3-(3-methylpiperidin-1-yl)propan-1-ol
英文别名
3-[(3S)-3-methylpiperidin-1-yl]propan-1-ol
(S)-3-(3-methylpiperidin-1-yl)propan-1-ol化学式
CAS
862311-76-0
化学式
C9H19NO
mdl
MFCD11613846
分子量
157.256
InChiKey
PSSJPGZIAICNGX-VIFPVBQESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    11
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    23.5
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    (S)-3-(3-methylpiperidin-1-yl)propan-1-ol 在 palladium 10% on activated carbon 、 氢气 、 sodium hydride 作用下, 以 N,N-二甲基甲酰胺 、 mineral oil 为溶剂, 反应 32.5h, 生成 (S)-2-methoxy-4-(3-(3-methylpiperidin-1-yl)propoxy)aniline
    参考文献:
    名称:
    COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF
    摘要:
    本发明涉及作为H3R拮抗剂的化合物(A)的公式,以及它们的制备和用途,并进一步涉及包含这些化合物的药物组合物及其用途作为组胺3受体(H3R)功能调节剂。本发明还涉及这些化合物或药物组合物在治疗或预防与人类H3R功能相关的某些疾病和疾病中的用途。
    公开号:
    US20200102289A1
  • 作为产物:
    描述:
    (S)-(+)-3-methylpiperidine mandelate3-溴-1-丙醇potassium carbonate 作用下, 以 四氢呋喃 为溶剂, 反应 30.0h, 以85%的产率得到(S)-3-(3-methylpiperidin-1-yl)propan-1-ol
    参考文献:
    名称:
    Fused ring 4-oxopyrimidine derivative
    摘要:
    本发明提供以下公式(I)所表示的化合物或其药学上可接受的盐,具有组织胺H3受体拮抗剂或逆激动剂活性,在代谢性疾病、循环系统疾病或神经系统疾病的预防或治疗中有用。【其中,例如,Ar是通过从苯中消除两个氢原子形成的二价基团,X1是氮原子、硫原子或氧原子,R1是5-至6-成员杂芳基团,环A是5-至6-成员杂芳基环,R2和R3是氨基或烷基氨基,X2由以下公式(II)表示:(其中R4和R5是较低烷基基团,n是从2到4的整数)。】
    公开号:
    US20050182045A1
点击查看最新优质反应信息

文献信息

  • Fused ring 4-oxopyrimidine derivative
    申请人:Nagase Tsuyoshi
    公开号:US20050182045A1
    公开(公告)日:2005-08-18
    The present invention provides a compound represented by formula (I) below, or a pharmaceutically acceptable salt thereof, which, having histamine H3 receptor antagonist or inverse agonist activity, is useful in the prophylaxis or therapy of metabolic diseases, circulatory diseases, or nervous system diseases. [where, for example, Ar is a divalent group formed by eliminating two hydrogen atoms from benzene, X 1 is a nitrogen atom, sulfur atom or oxygen atom, R 1 is a 5- to 6-membered heteroaryl group, Ring A is a 5- to 6-membered heteroaryl ring, R 2 and R 3 are amino groups or alkylamino groups, and X 2 is represented by formula (II): (where R 4 and R 5 are lower alkyl groups, and n is an integer from 2 to 4).]
    本发明提供以下公式(I)所表示的化合物或其药学上可接受的盐,具有组织胺H3受体拮抗剂或逆激动剂活性,在代谢性疾病、循环系统疾病或神经系统疾病的预防或治疗中有用。【其中,例如,Ar是通过从苯中消除两个氢原子形成的二价基团,X1是氮原子、硫原子或氧原子,R1是5-至6-成员杂芳基团,环A是5-至6-成员杂芳基环,R2和R3是氨基或烷基氨基,X2由以下公式(II)表示:(其中R4和R5是较低烷基基团,n是从2到4的整数)。】
  • Synthesis, structure–activity relationships, and biological profiles of a dihydrobenzoxathiin class of histamine H3 receptor inverse agonists
    作者:Takahide Sasaki、Toshiyuki Takahashi、Tsuyoshi Nagase、Takashi Mizutani、Sayaka Ito、Yuko Mitobe、Yasuhisa Miyamoto、Maki Kanesaka、Ryo Yoshimoto、Takeshi Tanaka、Norihiro Takenaga、Shigeru Tokita、Nagaaki Sato
    DOI:10.1016/j.bmcl.2009.05.101
    日期:2009.8
    human histamine H3 receptor inverse agonists. After systematic modification of lead 1a, the potent and selective histamine H3 inverse agonist 1-(3-4-[(2S,3S)-8-methoxy-3-methyl-4,4-dioxido-2,3-dihydro-1,4-benzoxathiin-2-yl]phenoxy}propyl)pyrrolidine (5k) was identified. Compound 5k showed good pharmacokinetic profiles and brain penetrability in laboratory animals. After 3 mg/kg oral administration of
    合成了一系列新颖的二氢苯并黄嘌呤衍生物,并将其评价为有效的人组胺H 3受体反向激动剂。铅1a的系统修饰后,有效的选择性组胺H 3反向激动剂1-(3- 4-[(2 S,3 S)-8-甲氧基-3-甲基-4,4-dioxido-2,3鉴定出了-二氢-1,4-苯并噻吨-2-基]苯氧基}丙基)吡咯烷(5k)。化合物5k在实验动物中显示出良好的药代动力学特征和脑穿透性。口服3k / kg的5k后,在大脑H 3含量较高的大鼠中观察到脑组胺水平显着升高 受体完全被占用。
  • Benzoxathiin derivative
    申请人:MSD. K. K.
    公开号:US08163770B2
    公开(公告)日:2012-04-24
    Disclosed is a compound represented by the formula (I) below and a pharmaceutically acceptable salt thereof. This compound is useful for treatment of obesity, diabetes and the like. [In the formula (I), Ar represents a benzene ring or the like; X1 represents a nitrogen atom, a sulfur atom or the like; R1 represents an aryl group or the like; X2 represents a group represented by the following formula (II): (wherein R4 and R5 respectively represent a lower alkyl group or the like, and m represents a number of 2-4) or the like; one of X and Y represents an oxygen atom and the other represents a sulfanyl group or the like; and X3-X6 respectively represent —CH—, a nitrogen atom or the like.
    本发明公开了一种化合物及其药学上可接受的盐,其化学式如下(I)。该化合物可用于治疗肥胖症、糖尿病等疾病。在公式(I)中,Ar代表苯环或类似物;X1代表氮原子、硫原子或类似物;R1代表芳基或类似物;X2代表由以下式子(II)表示的基团:(其中R4和R5分别表示低碳基或类似物,m表示2-4的数字)或类似物;X和Y中的一个代表氧原子,另一个代表硫基或类似物;X3-X6分别表示-CH-、氮原子或类似物。
  • Novel Benzoxathiine Derivative
    申请人:Mizutani Takashi
    公开号:US20100168156A1
    公开(公告)日:2010-07-01
    Disclosed is a compound represented by the formula (I) below and a pharmaceutically acceptable salt thereof. This compound is useful for treatment of obesity, diabetes and the like. [In the formula (I), Ar represents a benzene ring or the like; X 1 represents a nitrogen atom, a sulfur atom or the like; R1 represents an aryl group or the like; X 2 represents a group represented by the following formula (II): (wherein R 4 and R 5 respectively represent a lower alkyl group or the like, and m represents a number of 2-4) or the like; one of X and Y represents an oxygen atom and the other represents a sulfanyl group or the like; and X 3 -X 6 respectively represent —CH—, a nitrogen atom or the like.
    揭示了一种由下式(I)表示的化合物及其药学上可接受的盐。该化合物可用于治疗肥胖症、糖尿病等疾病。[在式(I)中,Ar代表苯环或类似物;X1代表氮原子、硫原子或类似物;R1代表芳基或类似物;X2代表由以下式(II)表示的基团:(其中R4和R5分别表示低碳基或类似物,m表示2-4的数)或类似物;X和Y中的一个代表氧原子,另一个代表硫基或类似物;X3-X6分别表示-CH-,氮原子或类似物。
  • Novel Piperidine Derivative
    申请人:Ishikawa Shiho
    公开号:US20090137576A1
    公开(公告)日:2009-05-28
    Disclosed is a substance having an antagonistic effect on the binding of histamine to a histamine H3 receptor or an inhibitory effect on the activity which a histamine H3 receptor constantly exhibits. A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof; (I) wherein R1 represents a phenyl group which may be substituted or the like and R2 represents a cyano group which may be substituted or the like, or R1 and R2 together form an aliphatic heterocylic ring which may be substituted; R3 represents a group represented by the formula (II-1) below; and all of X1 to X4 represent a carbon atom or the like: (II-1) where R4 and R5 represent a lower alkyl group or the like; and m1 represents an integer of 2 to 4.
    本发明涉及一种物质,其对组胺与组胺H3受体的结合具有拮抗作用,或对组胺H3受体不断表现的活性具有抑制作用。化合物由式(I)或其药学上可接受的盐表示;(I)其中R1代表可能被取代或类似的苯基团,R2代表可能被取代或类似的氰基团,或R1和R2一起形成可能被取代的脂肪族杂环环;R3代表由下式(II-1)表示的基团;X1到X4都表示碳原子或类似物:(II-1)其中R4和R5代表较低的烷基团或类似物;m1表示2到4的整数。
查看更多